OncoMatch/Clinical Trials/NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Is NCT05652335 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JNJ-79635322 for relapsed or refractory multiple myeloma.
Treatment: JNJ-79635322 — The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
have been treated with a proteasome inhibitor
Must have received: immunomodulatory drug
have been treated with an immunomodulatory drug (IMiD) agent
Must have received: anti-CD38-based therapy
have been treated with an anti-CD38-based therapy
Cannot have received: proteasome inhibitor
PI therapy within 14 days prior to the first dose of study treatment
Cannot have received: immunomodulatory drug
IMiD agent therapy within 7 days prior to the first dose of study treatment
Cannot have received: gene-modified adoptive cell therapy
Exception: not applicable for Part 2C participants
gene-modified adoptive cell therapy within 90 days
Cannot have received: CD3-redirecting therapy
Exception: not applicable for Part 2B or 2C participants
CD3-redirecting therapy within 21 days
Cannot have received: radiation therapy
radiotherapy within 14 days
Cannot have received: allogeneic transplant
Prior allogeneic transplant within 6 months before the start of study treatment administration
Cannot have received: autologous transplant
autologous transplant within 12 weeks before the start of study treatment administration
Lab requirements
Cardiac function
left ventricular ejection fraction (lvef) >=45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center · Irvine, California
- University of California San Francisco · San Francisco, California
- Colorado Blood Cancer Institute · Denver, Colorado
- Icahn School of Medicine at Mt. Sinai · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify